Sangamo BioSciences | SGMO - Fremdkapital





Fremdkapital Veränderung Datum
Alaunos Therapeutics USD 4.47M 5.85M 2022-06
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Alterity Therapeutics Limited AUD 43.68K 59.53K 2025-12
Amgen USD 51.89B 1.88B 2026-03
Bayer EUR 30.68B 1.15B 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Cipla INR 3.82B 840.2M 2026-03
Clal Biotechnology ILS 25.96M 18.48M 2023-12
Compugen USD 0 0 2024-12
CSL USD 10.42B 273M 2025-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Grifols EUR 9.95B 722.93M 2025-12
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
J&J USD 37.34B 183M 2026-06
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Merck USD 46.67B 77M 2026-03
Novartis USD 37.45B 7.86B 2026-03
Omeros USD 403.72M 27.2M 2024-06
Pfizer USD 60.57B 1.08B 2026-03
Roche Holding CHF 25.22B 2.21B 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 13.84B 1.88B 2026-03
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Tectonic Therapeutic USD 17K 26K 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12